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Murine Cancer Model 
Transgenesis 
A B S T R A C T   
Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer in adults and a leading cause 
of cancer-related deaths worldwide. Studies have shown that autophagy is significantly involved in carcino-
genesis, in particular, driven by activated RAS signaling. Autophagy related 7 (Atg7) is a critical component for 
the formation of autophagosome and required for autophagy processes. We investigated the role of autophagy in 
RAS-driven tumorigenesis in the liver, via the knockdown of Atg7 in the model. Transposon vectors encoding 
short hairpin RNAs targeting Atg7 (Atg7 shRNA) were constructed. Inhibition of autophagy via Atg7 knockdown 
was tested in Hep3B cells cultured in nutrient-starved medium. Formation of autophagosome was suppressed in 
nutrient-starved Hep3B cells expressing Atg7 shRNA, demonstrating that it efficiently inhibited autophagy in 
HCC cells. Transposons encoding Atg7 shRNA were mixed with those expressing HRASG12V and p53 shRNA, and 
subsequently used for hydrodynamic injection to 5-week-old C57BL/6 mice. Tumorigenesis in livers induced by 
HRASG12V and p53 shRNA was significantly suppressed by Atg7 knockdown. The inhibition of autophagy led to a 
decreased proliferation of cancer cells, as determined by Ki-67 staining. Our data indicate that knockdown of 
Atg7 led to a significant decrease in tumorigenesis in a murine HCC model induced by activated RAS. Inhibition 
of autophagosome formation is expected to be a therapeutic option for liver cancer.   
Introduction 
Hepatocellular Carcinoma (HCC) is the most common type of pri-
mary liver cancer in adults and causes about 800,000 deaths globally 
each year [1–6]. Genetic studies have revealed that initiation and pro-
gression of HCC involves genetic and epigenetic changes in various 
genes which lead to activation of diverse oncogenic signaling pathways 
[7–9]. The RAS signaling pathway promotes cellular proliferation, 
growth, and survival, which is found frequently activated in most 
human cancers including HCC [10]. As well, the signaling pathway 
regulates cancer metabolism and autophagy [11–13]. 
Autophagy is a cellular recycling process by which macromolecules 
and organelles can be degraded in lysosomes to sustain metabolism 
during starvation [14]. During the process, an isolated membrane ex-
pands and wraps around portions of the cytoplasm to form an auto-
phagosome, a double-membraned vesicle [15]. Autophagosome 
subsequently fuses with a lysosome to generate an autolysosome in 
which inner particles such as macromolecules and organelles are 
degraded by lysosomal proteases. In cancer cells with activated RAS 
signaling, autophagy is found frequently up-regulated, compared with 
that in normal cells, or cancer cells without activated RAS signaling [16, 
17]. Moreover, in murine xenograft and autochthonous models of 
RAS-driven pancreatic and lung cancers, inhibition of autophagy led to a 
substantial decrease in tumor growths [18,19]. In cancers showing 
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activated RAS signaling, autophagy was found essential for cell survival 
by regulating cellular energy metabolism [20–23]. 
Considering that the RAS signaling pathway is upregulated in more 
than 50% of HCC [10], we were curious about whether HCC with acti-
vated RAS signaling is also vulnerable to autophagic inhibition. For the 
purpose, we employed the hydrodynamics-based transfection method to 
develop a murine autochthonous HCC model driven by an activated 
RAS, and investigated effects of the inhibition of autophagy on the 
tumor development. 
Materials and methods 
Plasmids 
Plasmids used in this study have been previously described [24,25]. 
The open reading frame (ORF) of murine Atg7 was PCR-amplified from 
murine cDNAs and cloned into pcDNA3 vector. The ORF encoding 
GFP-LC3 was PCR-amplified from pEGFP-LC3 (Addgene #24,920) and 
placed immediately before shRNA-coding region. The target sequence in 
the murine Atg7 mRNA recognized by each Atg7 shRNA was listed in 
Supplementary Table 1. 
Animal experiment 
All experiments using mice were approved by the institution’s ani-
mal policy and welfare committee. Wild-type male C57BL/6 mice were 
purchased from Orient Bio (Korea). Animals were housed in an animal 
facility under a 12 h light/dark cycle and were provided food and water 
ad libitum. Hydrodynamic injection has also been previously described 
[25]. Briefly, DNA mixtures were suspended in lactated Ringer’s solu-
tion and subsequently injected into the lateral tail veins of male 
5–6-week-old mice (0.1 mL/g body weight). Mice were randomly 
assigned to hydrodynamic injection. Mice were treated with chloroquine 
(Sigma-Aldrich Inc., St Louis, MO) at a daily dose of 100 mg/kg body 
weight via intraperitoneal injection. 
Transfection and Western blotting 
Cells were plated 3 × 105 cells per well on 6 well plate one day prior 
to transfection so that the cells were approximately 80% confluent on 
the day of transfection. Cells were transiently transfected with 2 μg of 
DNA using 6μl FuGENE® HD Transfection Reagent (Promega, Madison, 
WI, USA) according to the manufacturer’s instructions. Transfected cells 
were harvested 2 days post-transfection using the 10X RIPA buffer (Cell 
Signaling, Denvers, MA, USA) according to the manufacturer’s in-
structions. Cells were briefly washed with PBS to remove residual media. 
200 μl of 1X RIPA buffed and diluted in DW were added to each well and 
then were incubated on ice for 5 min. Afterwards, cells were scrapped 
with a scrapper and transferred to a new tube. For 30–60 min, cells were 
placed on ice, and extracts were centrifuged for 10 min at 14,000 RPM in 
a cold microcentrifuge. Finally, supernatants were removed for use. 
Western blot experiments were performed using standard methods. 
Primary antibodies used are anti-ATG7 (Wako 013–22,831, 1/1000 
dilution), anti-GAPDH (CST #2118, 1/3000 dilution), anti-LC3B (CST 
#2775, 1/1000 dilution), and anti-p62 (ABCAM ab56416, 1/200 dilu-
tion) antibodies. 
Fluorescence imaging 
Fluorescence imaging of GFP was performed to confirm transfection 
of cells using an inverted microscope (IX71, Olympus, Japan) equipped 
with a 10X objective lens. For imaging of GFP-LC3 puncta within cells, 
transfected cells were fixed with 4% paraformaldehyde, stained with 
4′,6-diamidino-2-phenylindole (DAPI) for two minutes at room tem-
perature, and then imaged using an inverted laser-scanning microscope 
(Zeiss LSM 510), equipped with a 40X objective. 
Liver harvesting and tissue processing 
Mice were deeply anesthetized by intraperitoneal injection of Zoletil 
(30 mg/kg) and xylazine (10 mg/kg). A midline laparotomy incision was 
performed, and livers were removed and photographed. Pieces of 
extracted mouse liver samples were immersed in freshly prepared 10% 
neutral-buffered formalin overnight. Fixed tissue samples were 
embedded in paraffin and serially sectioned into 4 µm–thick slices. Slices 
were stained with hematoxylin & eosin (H&E). 
Immunohistochemical analyses for GFP and KI-67 
For immunohistochemistry, paraffin-embedded sections were 
deparaffinized in xylene and rehydrated through a gradual decrease in 
ethanol concentration. Antigen epitopes were then unmasked using a 10 
mM sodium citrate buffer (pH 6.0) incubation procedure, after which 
sections were incubated overnight at 4 ◦C with the primary antibody 
against GFP (CST #2555). After incubation with primary antibodies, 
sections were incubated with the biotinylated secondary antibody fol-
lowed by treatment with freshly prepared DAB substrates (Vector Lab-
oratories, USA). Sections were lightly counter-stained with hematoxylin 
and mounted. For Ki-67 assay, the sections were incubated overnight at 
4 ◦C using anti-Ki-67 primary antibodies (CST #9449). After primary 
antibody incubation, sections were incubated with the appropriate 
biotinylated secondary antibodies followed by the treatment with 
freshly prepared DAB substrates (SK-4100; Vector Laboratories). Sec-
tions were lightly counter-stained with hematoxylin and mounted. 
Positively stained nuclei in a field view under a 400 × magnification was 
counted. Area of view was randomly chosen. Slides were photographed 
using a microscope (Eclipse Ti; Nikon, Tokyo, Japan) equipped with a 
digital camera. 
Statistical analysis 
The liver weight/body weight ratio (LW/BW) data were expressed as 
the mean ± SEM with a sample size of n = 10. Statistical analyses were 
conducted via an unpaired parametric Student’s t-test. Significant dif-
ferences between two groups were noted by asterisks (*, p < 0.05; **, p 
< 0.01). 
Results 
Knockdown of Atg7 using short hairpin RNA 
To investigate the effect of autophagy inhibition on the development 
of liver cancer, we chose to down-regulate Atg7 using short hairpin RNA 
(shRNA). Atg7 is an essential component for the autophagosome for-
mation, and genetic abrasion of Atg7 successfully inhibited autophagy 
processes in murine models [26]. We selected 4 kinds of shRNAs tar-
geting different locations in the murine Atg7 mRNA. To test knockdown 
efficiency of each Atg7 shRNA, NIH3T3 cells was co-transfected with 
plasmids encoding each Atg7 shRNA and those expressing murine Atg7 
(Fig. 1A). Transfection of cells with plasmids expressing individual 
shRNA was verified using a co-expressed reporter protein, green fluo-
rescent protein (GFP) (Fig. 1B). We found that the knockdown of Atg7 
was efficiently achieved by the Atg7 shRNAs that we constructed, except 
for one case (Fig. 1C and Supplementary Figure 1). Among the three 
shRNAs that efficiently down-regulated Atg7, shAtg7–2 was the most 
effective, and thus was chosen for following study. 
Knockdown of Atg7 inhibits autophagic processes in HCC cells upon 
starvation 
To verify that knockdown of Atg7 inhibits autophagy in HCC cells, 
Hep3B cells were transfected with plasmids simultaneously expressing 
Atg7 shRNA and GFP-fused LC3 (GFP-LC3). At 24 h after transfection, 
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cells were subjected to starvation for 4 h to activate autophagy (Fig. 2A). 
GFP-LC3 is a marker protein for active autophagic processes which al-
lows autophagosome structures to be visualized as green fluorescent 
punctate signals (also known as GFP-LC3 puncta) under fluorescence 
microscopy [27]. Following starvation, Hep3B cells expressing control 
shRNA (shCon) showed numerous GFP-LC3 puncta within cells, whereas 
those expressing Atg7 shRNA (shAtg7–2) rarely revealed green fluo-
rescent puncta (Fig. 2B). As well, shAtg7–2 expression in 
nutrient-deprived Hep3B cells led to an elevated level of p62, an indi-
cator for autophagy inhibition (Fig. 2C) [28,29]. Further, starvation led 
to an increase in the LC3-II level in Hep3B cells expressing control 
shRNA, which indicates up-regulation of autophagosome formation 
[29]. However, starvation failed to increase the LC3-II level in Hep3B 
cells expressing shAtg7–2, which strongly suggests that formation of 
autophagosome was efficiently suppressed by the Atg7 knockdown 
(Fig. 2C and Supplementary Figure 2). Overall, the data demonstrate 
that the Atg7 shRNA can efficiently suppress autophagy activity in HCC 
cells via down-regulation of Atg7. 
Knockdown of Atg7 suppresses hepatocarcinogenesis in mice 
To investigate whether inhibition of autophagy affects tumor 
development driven by activated RAS signaling in the liver, we 
employed a simple liver-specific transgenic approach in which trans-
posons encoding a constitutively active form of RAS (HRASG12V) and 
p53 shRNA were co-delivered to murine livers with those encoding Atg7 
shRNA through hydrodynamic tail vein injection (HTVI) (Fig. 3A). Ten 
mice were assigned to each group. When livers were harvested at 5 
weeks after the hydrodynamic injection, we found that expression of 
shAtg7–2 significantly inhibited hepatic tumorigenesis induced by 
HRASG12V and p53 shRNA, when compared with the control group 
(Fig. 3B). Numbers and sizes of tumors were notably reduced in the 
livers expressing shAtg7–2 compared with the control group (Table 1). 
Liver weight per body weight (LW/BW), often used to evaluate tumor 
burden in liver, was also significantly reduced in the Atg7 knockdown 
group, compared with the control (Fig. 3C). 
To confirm that autophagy inhibition suppresses tumorigenesis 
induced by HRASG12V and p53 shRNA in the liver, mice were treated 
with an autophagy inhibitor, chloroquine following HTVI [30]. In line 
with the tumor suppression by the stable knockdown of Atg7 in the 
model, the treatment with chloroquine also suppressed tumor growth in 
the model (Supplementary Figure 3). 
Knockdown of Atg7 suppresses cellular proliferation in HCC cells 
Morphological differences in cancer cells were not apparent between 
the shAtg7–2 group and control (Fig. 4A). All tumor nodules were GFP- 
positive, confirming shRNA expression in the tumors. To investigate the 
cellular mechanism underlying reduced tumor growths in the shAtg7–2 
group, tumor tissues were analyzed for cellular proliferation and 
apoptosis. Of note, cellular proliferation was significantly lower in the 
shAtg7–2 group compared with that in the control, when determined by 
Ki-67 nuclear staining (Fig. 4B and C), while apoptosis levels were not 
significantly different between the two groups. Thus, the data suggest 
that in the liver cancer induced by activated RAS signaling, inhibition of 
autophagy suppressed tumor development via down regulating cellular 
proliferation. To further confirm that Atg7 knockdown can affect pro-
liferation of HCC cells, MTT assay was performed using Hep3B cells 
stably expressing shAtg7–2. In line with the in vivo finding, inhibition of 
Atg7 in the HCC cells led to decreased cell proliferation compared with 
Hep3B cells expressing control shRNA (Supplementary Figure 4). 
Fig. 1. Efficiencies of Atg7 knockdown by shRNAs. (A) Plasmids used for the 
transfection experiment. (B) Bright field (upper panels) and fluorescence (lower 
panels) images of NIH3T3 cells transfected with indicated shRNAs. The shCon 
indicates control shRNA. (C) Western blots showing expression levels of Atg7 in 
cells transfected with plasmids encoding indicated shRNA (1, shAtg7–1; 2, 
shAtg7–2; 3, shAtg7–3; 4, shAtg7–4). 
Fig. 2. Inhibition of autophagy by Atg7 shRNA (A) Schematic illustration of the 
experimental procedure. Hep3B cells were transfected with plasmids expressing 
GFP-LC3 and shRNA and then subjected to starvation (B) Representative fluo-
rescence images of Hep3B cells transfected with plasmids encoding indicated 
shRNA upon starvation. Cells were stained with DAPI to reveal nuclei (blue). 
Scale bar, 10 μm. (C) Western blots showing expression levels of LC3-I, LC3-II, 
and p62 in Hep3B cells depending on starvation (+ indicates starvation) and 
expression of shAtg7–2 (+ indicates shAtg7–2 expression). 
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Discussion 
The RAS signaling pathway is activated through receptor tyrosine 
kinases (RTKs) [31,32]. Ligand binding to the receptor induces receptor 
dimerization which leads to transphosphorylation at tyrosine residues of 
the cytoplasmic tails by the receptor’s intracellular tyrosine kinase ac-
tivity [33]. The phosphorylated tyrosine residues recruit the 
Grb2/Shc/SOS protein complex to plasma membrane, which converts 
GDP-bound inactive RAS to GTP-bound active RAS. This event leads to 
subsequent activation of the mitogen-activated protein (MAP) kinase 
signaling cascade through the RAF-MEK-ERK axis. 
The importance of the RAS signaling pathway in human HCC has 
been neglected for a long time, understandably due to low frequencies of 
mutation in RAS and RAF in HCC [34]. However, based on MEK/ERK 
expression and phosphorylation, the RAS signaling pathway is found 
activated in approximately 50% of early-stage HCC and in most 
advanced-stage HCC [35,36]. The activity of the RAS signaling pathway 
in HCC can be elevated by hepatitis viral proteins, dysregulated RTKs, 
inactivation of Raf kinase inhibitor proteins, and etc. [37]. 
RAS signaling is involved in cell growth and proliferation [10]. The 
signaling pathway is also highly involved in regulating cancer meta-
bolism [38,39]. The Ras signaling can induce activation of the glycolytic 
pathway and glutamine metabolism pathways which cancers preferen-
tially utilize to meet their high metabolic needs. 
Cancer with activated RAS signaling is heavily dependent on auto-
phagy, as verified in murine models of RAS-driven pancreatic and lung 
cancers which showed high susceptibilities to autophagic suppression 
[18,19,40]. Autophagy can contribute to tumor growth during carci-
nogenesis by supplying neoplastic cells with nutrients such as amino 
acids, free fatty acids (FFA) and glucose. Consistent with cancer models 
of other tissues, our data showed that tumor development in murine 
livers driven by activated RAS signaling was significantly suppressed by 
the inhibition of autophagy through Atg7 knockdown. 
Although our study supports pro-tumorigenic effects of autophagy, 
tumor-suppressive roles of autophagy have also been reported in HCC. 
Heterozygous deletion of the gene encoding Beclin1, another key 
molecule in the autophagy pathway, induced development of sponta-
neous tumors in the liver, [41,42]. Likewise, mice with systemic mosaic 
deletion of Atg5 or liver-specific deletion of Atg7 developed benign 
hepatic adenomas [43]. Thus, it is presumed that functional autophagy 
is required to suppress tumorigenesis in the liver and its deregulation 
can promotes neoplastic transformation of hepatocytes. Autophagy 
removes cellular wastes and damaged proteins, accumulation of which 
can cause oxidative damages to DNA, leading to genomic instability [44, 
45]. In line with this, mice with liver-specific deletion of Atg5 or Atg7 
showed increased oxidative DNA damages in the livers [46]. 
On the contrary, autophagy contributes to survival of cancer cells by 
providing them with nutrients required for increased energy metabolism 
and removing toxic reactive oxygen radicals and mis-folded proteins 
Fig. 3. Inhibition of autophagy led to tumor suppression in the liver. (A) 
Schematic illustration of the experimental procedure. Liver tumors were 
induced by HRASG12V and shp53. Atg7 shRNA (or control shRNA) was 
expressed in the tumor to investigate effects of Atg7 knockdown on liver cancer. 
(B) Gross morphology of representative livers expressing either control shRNA 
(shCon) and Atg7 shRNA (shAtg7–2). Livers were harvested at 5 weeks after 
hydrodynamic injection. (n = 10 for each group) (C) Liver weight/body weight 
(LW/BW) ratios of mice expressing shCon and shAtg7–2. The graph represents 
the mean ± SEM (n = 10 livers per group) (*, p < 0.05). 
Table 1 
Tumor nodules in a mouse model of HCC following ATG7 knockdown.  
Group Total # of tumors # of tumors over 3 mm in diameter 
shCon TMTC >10 
shAtg7–2 2 ± 0.5 0 
TMTC, Too many to count. 
Fig. 4. Microscopic examination of liver tumors. (A) H&E and IHC image of 
paraffin-embedded sections from shCon and shAtg7–2 tumors. GFP was used as 
a reporter for shRNA expression. Scale bar, 200 µm. Inhibition of autophagy led 
to tumor suppression in the liver. (B) Representative images of Ki-67 staining in 
the shCon and shAtg7–2 tumors. Scale bar, 50 µm. (C) Quantification of nuclei 
positive for Ki-67 staining in tumors of each group. The values represent per-
centages of Ki-67-positivity among the total nuclei. The graphs represent the 
mean ± SEM. (**, p < 0.01). 
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[47,48]. Thus, inhibition of autophagy can render cancer cells suscep-
tible to cytotoxic substances. It is tempting to think that autophagy in-
hibition initiates neoplastic transformation in normal hepatocytes by 
inducing oncogenic mutations, however, once oncogenic drivers have 
been established, sustained inhibition of autophagy will exert cytotoxic 
effects on tumor cells, hindering tumor growth. Further mechanistic 
studies are required to precisely determine the role of autophagy in HCC. 
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